联影医疗（United Imaging Healthcare） · 巴西（Brazil）

United Imaging's 2024 annual results release names Brazil among strategic emerging markets with 'multiple system installations completed'. It entered Brazil in 2024 through an exclusive partnership with Strattner as sole distributor; the ANVISA-approved portfolio includes the uMR Omega (first 3T ultra-wide-bore MR in Brazil, running the uAIFI AI platform), the uCT550 and post-processing servers, with whole-body PET/CT then in ANVISA approval. Note the standalone uAI software from United Imaging Intelligence is not commercially available in Brazil.

AI medical imaging equipment enters Brazil's emerging market; details on specific hospitals, training, and localized services to be supplemented.

结构化字段

东道国

巴西（Brazil）

区域

拉丁美洲

AI 赛道

医疗健康 AI

进入方式

产品与服务出口

进入年份

2024

落地状态

已公布（含具体安排）

资本流向

中国 → 东道国（对外部署）

企业集团

United Imaging

本地伙伴

Company disclosure: 2024 revenue CNY 10.30 billion; overseas revenue CNY 2.27 billion (+35.07% YoY). Brazil: exclusive distribution via Strattner from 2024, multiple systems installed, first 3T ultra-wide-bore MR in the country; unit counts and amounts not disclosed.

来源与备注

记录备注：LA-045: Newly added, yellow candidate. Official sources prove multiple system installations and AI capabilities in Brazil, but lack specific customer project pages; recommend as candidate. ⚠ 2026-09-13 全库回扫处置：经对抗复核判定为 SELF_ATTESTED_ONLY。四条来源去重后仅 4 条 URL，扣除死链与已漂移列表页后实际可用 2 条，回溯到 2 个事实源头——联影自家业绩通稿与联影巴西+Strattner 联合传播，均系交易当事方，独立第三方来源为 0。唯一直接断言 multiple system installations completed 的句子出自企业自家 News Center，属自证；medicinasa 一文为交易对手方供稿的品牌内容，原文只称已获 ANVISA 批准、已可供应国内市场，仅支撑"已宣布/可售"，不支撑"多台已安装在用"。据此本次将 deployment_status 由 Landed 降为 Announced-concrete，reliability 由 High 降为 Low；删除死链 investor-relations/reports 与已漂移的 investor-relations 列表页，n_sources 由 5 修正为 2；partner_primary_type 由 hospital_health 改为 distributor_channel，n_local_partners 与 partner_has_hospital 回退为 1 与 0（其依据的 JPR 2025 五家巴西临床客户在四条来源中 0 次出现）。恢复 Landed 须取得逐字证明某台设备在巴西某机构已安装并在运营的独立材料：署名记者实地报道、医院或诊所自身设备页、公立采购或招标公告；ANVISA 在册记录只能坐实"合法可售"，不能升至 Landed。

本页内容整理自公开报道与企业披露，不构成法律意见或投资建议；对外引用时请连同来源链接一并给出。